These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20004545)

  • 1. Testing whether decision aids introduce cognitive biases: results of a randomized trial.
    Ubel PA; Smith DM; Zikmund-Fisher BJ; Derry HA; McClure J; Stark A; Wiese C; Greene S; Jankovic A; Fagerlin A
    Patient Educ Couns; 2010 Aug; 80(2):158-63. PubMed ID: 20004545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
    Fagerlin A; Zikmund-Fisher BJ; Nair V; Derry HA; McClure JB; Greene S; Stark A; Hensley Alford S; Lantz P; Hayes DF; Wiese C; Claud Zweig S; Pitsch R; Jankovic A; Ubel PA
    Breast Cancer Res Treat; 2010 Feb; 119(3):613-20. PubMed ID: 19908143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs.
    Zikmund-Fisher BJ; Ubel PA; Smith DM; Derry HA; McClure JB; Stark A; Pitsch RK; Fagerlin A
    Patient Educ Couns; 2008 Nov; 73(2):209-14. PubMed ID: 18602242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
    Korfage IJ; Fuhrel-Forbis A; Ubel PA; Zikmund-Fisher BJ; Greene SM; McClure JB; Smith DM; Alford SH; Fagerlin A
    Breast Cancer Res; 2013; 15(5):R74. PubMed ID: 24004815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
    Juraskova I; Butow P; Lopez A; Seccombe M; Coates A; Boyle F; McCarthy N; Reaby L; Forbes JF
    Health Expect; 2008 Sep; 11(3):252-62. PubMed ID: 18816321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide.
    McKay A; Martin W; Latosinsky S
    Breast Cancer Res Treat; 2005 Nov; 94(2):153-9. PubMed ID: 16261414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
    Gail MH; Costantino JP; Bryant J; Croyle R; Freedman L; Helzlsouer K; Vogel V
    J Natl Cancer Inst; 1999 Nov; 91(21):1829-46. PubMed ID: 10547390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.
    McIntosh JG; Minshall J; Saya S; Bickerstaffe A; Hewabandu N; Qama A; Emery JD
    Br J Gen Pract; 2019 Dec; 69(689):e836-e842. PubMed ID: 31636127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2013 Nov; 159(10):698-708. PubMed ID: 24061412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge of Potential Harms and Benefits of Tamoxifen among Women Considering Breast Cancer Preventive Therapy.
    Thorneloe RJ; Hall LH; Walter FM; Side L; Lloyd KE; Smith SG;
    Cancer Prev Res (Phila); 2020 Apr; 13(4):411-422. PubMed ID: 31988145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
    JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer anxiety's associations with responses to a chemoprevention decision aid.
    Dillard AJ; Scherer L; Ubel PA; Smith DM; Zikmund-Fisher BJ; McClure JB; Greene S; Stark A; Fagerlin A
    Soc Sci Med; 2013 Jan; 77():13-9. PubMed ID: 23200299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen infrequently used by women at risk for breast cancer.
    Dreyfuss JH
    CA Cancer J Clin; 2010; 60(4):204-6. PubMed ID: 20530798
    [No Abstract]   [Full Text] [Related]  

  • 15. Breast cancer risk reduction: what do we know and where should we go?
    Prout MN
    Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Web-based decision aids to support breast cancer screening decisions: systematic review and meta-analysis.
    Yu L; Li P; Yang S; Guo P; Zhang X; Liu N; Wang J; Zhang W
    J Comp Eff Res; 2020 Oct; 9(14):985-1002. PubMed ID: 33025800
    [No Abstract]   [Full Text] [Related]  

  • 18. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.
    Paterniti DA; Melnikow J; Nuovo J; Henderson S; DeGregorio M; Kuppermann M; Nease R
    Ethn Dis; 2005; 15(3):365-72. PubMed ID: 16108294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision making in the context of breast cancer chemoprevention: patient perceptions and the meaning of risk.
    Holmberg C
    Am Soc Clin Oncol Educ Book; 2015; ():e59-64. PubMed ID: 25993227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Information needs and preferences of low and high literacy consumers for decisions about colorectal cancer screening: utilizing a linguistic model.
    Smith SK; Trevena L; Nutbeam D; Barratt A; McCaffery KJ
    Health Expect; 2008 Jun; 11(2):123-36. PubMed ID: 18494957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.